Skip to main content

Xtant Medical Announces Fourth Quarter and Full Year 2022 Financial Results

BELGRADE, Mont., March 07, 2023 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the fourth quarter and year ended December 31, 2022.

“Highlighted by strong fourth quarter revenue results and last week’s acquisition of the Coflex® product line, we are executing on our key growth initiatives,” said Sean Browne, President and CEO of Xtant Medical. “We continue to generate robust demand for our biologics products, which grew 14% for the quarter, and improve our operating efficiencies by increasing our production capacity that now has us well-positioned to sustain our momentum in 2023. Additionally, with the addition of the Coflex product line, we significantly enhanced our fixation offering at ASCs and outpatient facilities. We are excited to add proven treatment devices while expanding our commercial team and distributor network, all of which are core focus areas to our long-term growth strategy.”

Fourth Quarter and Full Year 2022 Financial Results

Fourth quarter 2022 revenue grew 9% to $15.3 million, compared to $14.0 million for the same quarter in 2021. Full year 2022 revenue was $58.0 million, compared to $55.3 million for 2021. The increase in revenue was largely attributable to our new products.

Gross margin for the fourth quarter of 2022 was 54.4%, compared to 55.1% for the same period in 2021 and 55.4% for the full year 2022, compared to 58.8% for the full year 2021. These decreases were primarily attributable to higher production costs with increased charges for excess and obsolete inventory also contributing to the full year decline.

Operating expenses for the fourth quarter of 2022 totaled $10.0 million, compared to $9.6 million for the fourth quarter of 2021, and were $38.9 million for the full year 2022 compared to $36.3 million for the full year 2021. The increase for the quarterly comparison was primarily due to higher independent agent commission expenses. The increase for the annual comparison was primarily due to higher independent agent commission expenses and employee compensation expenses as well as costs related to ERP system upgrades, partially offset by lower legal settlement expenses.

Fourth quarter 2022 net loss totaled $2.2 million, or $0.02 per share, compared to the fourth quarter 2021 net loss of $2.3 million, or $0.03 per share. Net loss for 2022 was $8.5 million, or $0.09 per share, compared to a net loss of $4.8 million, or $0.06 per share, for 2021.

Non-GAAP Adjusted EBITDA for the fourth quarter of 2022 totaled a loss of $0.8 million, compared to Non-GAAP Adjusted EBITDA loss of $0.9 million for the same period in 2021. Non-GAAP Adjusted EBITDA for 2022 totaled a loss of $3.0 million, compared to a gain of $0.3 million for 2021. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation and legal settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

Conference Call

Xtant Medical will host a webcast and conference call to discuss the fourth quarter and full year 2022 financial results on Tuesday, March 7, 2023 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s belief that it is continuing to generate robust demand for its biologics products and improve its operating efficiencies by increasing its production capacity and is well-positioned to sustain its momentum in 2023. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; its ability to increase or maintain revenue; risks associated with its recent acquisition of the Coflex® product line; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory if revenues continue to decrease; the ability to remain competitive; the ability to innovate, develop and introduce new products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company’s dependence on key independent agents for a significant portion of its revenue; the effect of COVID-19, labor and hospital staffing shortages on the Company’s business, operating results and financial condition, especially when they affect key markets; the Company’s ability to implement successfully its future growth initiatives and risks associated therewith; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company’s financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC) on March 7, 2023 and subsequent SEC filings by the Company. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David Carey
Lazar FINN Partners
Ph: 212-867-1762
Email: david.carey@finnpartners.com 

XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except number of shares and par value)
  As of
December 31, 2022
 As of
December 31, 2021
     
ASSETS    
Current Assets:    
Cash and cash equivalents $20,298  $18,243 
Restricted cash  209   144 
Trade accounts receivable, net of allowance for credit losses of $515 and doubtful accounts of $552, respectively  10,853   7,154 
Inventories  17,285   17,945 
Prepaid and other current assets  673   844 
Total current assets  49,318   44,330 
     
Property and equipment, net  5,785   5,212 
Right-of -use asset, net  1,380   1,258 
Other assets  197   287 
Intangible assets, net  344   400 
Goodwill  3,205   3,205 
Total Assets $60,229  $54,692 
     
LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)    
Current Liabilities:    
Accounts payable $3,490  $2,615 
Accrued liabilities  5,496   4,349 
Current portion of lease liability  458   462 
Finance lease obiligations  62   31 
Line of credit  3,379   3,620 
Current portion of long-term debt  2,333    
Total current liabilities  15,218   11,077 
Long-term Liabilities:    
Lease liability, less current portion  972   842 
Financing lease obligations, net  181   103 
Long-term debt, plus premium and less issuance costs  9,687   11,787 
Total Liabilities  26,058   23,809 
     
Stockholders’ Equity    
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.000001 par value; 300,000,000 shares authorized; 108,874,803 shares issued and outstanding as of December 31, 2022 and 87,068,980 shares issued and outstanding as of December 31, 2021      
Additional paid-in capital  277,841   266,068 
Accumulated deficit  (243,670)  (235,185)
Total Stockholders’ Equity  34,171   30,883 
     
Total Liabilities & Stockholders’ Equity $60,229  $54,692 
     

XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except number of shares and per share amounts)
       
  Three Months Ended
December 31,

  Twelve Months Ended
December 31,

 
   2022   2021   2022   2021 
Revenue        
Orthopedic product sales $15,269  $13,953  $57,958  $55,146 
Other revenue  1   17   11   117 
Total revenue  15,270   13,970   57,969   55,263 
         
Cost of sales  6,964   6,276   25,832   22,773 
Gross profit  8,306   7,694   32,137   32,490 
         
Gross profit %  54.4%   55.1%   55.4%   58.8% 
         
Operating expenses        
General and administrative  3,966   4,142   15,462   14,449 
Sales and marketing  5,832   5,314   22,515   21,025 
Research and development  232   151   915   870 
Total operating expenses  10,030   9,607   38,892   36,344 
         
Income (Loss) from operations  (1,724)  (1,913)  (6,755)  (3,854)
         
Other Expense        
Interest expense  (495)  (466)  (1,692)  (995)
Interest income  31      31    
Total Other Expense  (464)  (466)  (1,661)  (995)
Net Loss Before Provision for Income Taxes  (2,188)  (2,379)  (8,416)  (4,849)
         
Provision for income taxes        
Current and deferred  (21)  95   (69)   
Net Loss $(2,209) $(2,284) $(8,485) $(4,849)
         
Net loss per share:        
Basic $(0.02) $(0.03) $(0.09) $(0.06)
Dilutive $(0.02) $(0.03) $(0.09) $(0.06)
         
Shares used in the computation:        
Basic  108,339,486   87,027,466   94,085,197   85,456,175 
Dilutive  108,339,486   87,027,466   94,085,197   85,456,175 
         

XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
 Twelve Months Ended
December 31,

 
  2022   2021 
Operating activities:   
Net loss$(8,485) $(4,849)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:   
Depreciation and amortization 1,292   1,332 
Gain on disposal of fixed assets (93)  (86)
Non-cash interest 233   147 
Non-cash rent expense 4   9 
Stock-based compensation 2,464   2,209 
Provision for reserve on accounts receivable 243   45 
Provision for excess and obsolete inventory 1,812   839 
    
Changes in operating assets and liabilities:   
Accounts receivable (3,941)  (319)
Inventories (1,152)  2,624 
Prepaid and other assets 261   (67)
Accounts payable 875   (332)
Accrued liabilities 1,146   (1,113)
Net cash (used in)provided by operating activities (5,341)  439 
Investing activities:   
Purchases of property and equipment (1,764)  (2,115)
Proceeds from sale of fixed assets 205   225 
Net cash used in investing activities (1,559)  (1,890)
Financing activities:   
Payment of taxes from withholding of common stock on vesting of restricted stock units    (201)
Payments on financing leases (50)  (50)
Payments on long-term debt    (411)
Borrowings on line of credit 54,229   36,361 
Repayments on line of credit (54,470)  (36,492)
Costs associated with debt restructuring    (136)
Proceeds from issuance of common stock, net of issuance costs 9,311   18,426 
Proceeds from exercise of common stock warrants     
Net cash provided by financing activities 9,020   17,497 
    
Net change in cash and cash equivalents and restricted cash 2,120   16,046 
Cash and cash equivalents and restricted cash at beginning of year 18,387   2,341 
Cash and cash equivalents and restricted cash at end of year$20,507  $18,387 
    
    
Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets   
Cash and cash equivalents 20,298   18,243 
Restricted cash 209   144 
Total cash and restricted cash reported in the consolidated balance sheets$20,507  $18,387 
    

XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(Unaudited, in thousands)
         
  Three Months Ended December 31, Twelve Months Ended December 31,
   2022   2021   2022   2021 
         
Net Loss $(2,209) $(2,284) $(8,485) $(4,849)
         
Other expense        (2)  62 
Depreciation and amortization  322   291   1,293   1,332 
Interest expense  463   466   1,661   995 
Tax expense  21   (95)  69    
Non-GAAP EBITDA  (1,403)  (1,622)  (5,464)  (2,460)
         
Non-GAAP EBITDA/Total revenue  -9.2%   -11.6%   -9.4%   -10.4% 
         
NON-GAAP ADJUSTED EBITDA CALCULATION         
Non-cash compensation  639   707   2,464   2,209 
Legal settlements           550 
Non-GAAP Adjusted EBITDA $(764) $(915) $(3,000) $299 
         
Non-GAAP Adjusted EBITDA/Total revenue  -5.0%   -3.5%   -5.2%   -4.9% 
         

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.